Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retrieval of chronic hepatitis C patients. A manifesto for action to eliminate hepatitis C in the Netherlands: the CELINE project.
van Dijk M, Kracht PAM, Arends JE, Blokzijl H, Burger DM, van Erpecum KJ, van Hoek B, de Knegt RJ, Posthouwer D, Ramsoekh D, Rijnders BJA, Schinkel J, Willemse SB, van der Valk M, Drenth JPH, Behalf Of The HepNed Study Group O. van Dijk M, et al. Among authors: schinkel j. Neth J Med. 2019 May;77(4):131-138. Neth J Med. 2019. PMID: 31502544 Free article.
Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor.
de Bruijne J, Bergmann JF, Weegink CJ, van Nieuwkerk CM, de Knegt RJ, Komoda Y, van de Wetering de Rooij JJ, van Vliet A, Jansen PL, Molenkamp R, Schinkel J, Reesink H, Janssen HL. de Bruijne J, et al. Among authors: schinkel j. Antivir Ther. 2010;15(5):765-73. doi: 10.3851/IMP1606. Antivir Ther. 2010. PMID: 20710058 Clinical Trial.
Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
Hotho DM, de Bruijne J, O'Farrell AM, Boyea T, Li J, Bracken M, Li X, Campbell D, Guler HP, Weegink CJ, Schinkel J, Molenkamp R, van de Wetering de Rooij J, van Vliet A, Janssen HL, de Knegt RJ, Reesink HW. Hotho DM, et al. Among authors: schinkel j. Antivir Ther. 2012;17(2):365-75. doi: 10.3851/IMP1989. Epub 2011 Nov 30. Antivir Ther. 2012. PMID: 22293533 Clinical Trial.
[New class of medicines for chronic hepatitis C].
Aronson SJ, de Bruijne J, Schinkel J, Weegink CJ, van der Valk M, Reesink HW. Aronson SJ, et al. Among authors: schinkel j. Ned Tijdschr Geneeskd. 2012;156(10):A3840. Ned Tijdschr Geneeskd. 2012. PMID: 22394440 Review. Dutch.
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
de Bruijne J, Thomas XV, Rebers SP, Weegink CJ, Treitel MA, Hughes E, Bergmann JF, de Knegt RJ, Janssen HL, Reesink HW, Molenkamp R, Schinkel J. de Bruijne J, et al. Among authors: schinkel j. J Viral Hepat. 2013 Nov;20(11):779-89. doi: 10.1111/jvh.12104. Epub 2013 Jun 27. J Viral Hepat. 2013. PMID: 24168257 Clinical Trial.
192 results